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Diabetes mellitus is the most common endocrine disease. It is 
the fourth leading cause of death by disea.se in western countries 
and it is a worldwide public health problem.H 
Prolongation of life is achieved by insulin therapy, but an 
increasing number of diabetic patients are treated for the compli-
cations associated with the disease, including blindness and end-
stage renal failure. Fifty percent of all patients with diabetes 
develop renal failure in their lifetime.I-5 
In patients with Type I diabetes mellitus. insulin production 
progressively declines and fmally disappears as the beta cells 
within the islets are destroyed by an autoimmune process which 
results from a complex interplay between genetic and unknown 
environmental factors.6-' Replacement therapy with exogenous 
insulin has prevented acute death but is imperfect and has been 
ineffective in preventing the chronic complications of the disease. -
Thus, altemative methods for total endocrine replacement have . 
been explored, including transplantation of isolated islets as a free 
graft.s 
The idea of transplanting pancreatic tissue to reverse diabetes 
is a century old~fl and recent reviews on the subject are: 
available.n -15 Procedures for islet isolationl 6-17 have improved 
significantly during the last decadelll-30 and the use of more 
powerful immunosuppressive agents such as cyclosporinel6.27.3I-
" or FK ;0634-36 have resulted in prolonged human islet allograft 
survival. Insulin independence3I.33-37- was obtained in some pa-
tients indicating that it is possible to replace the endocrine 
function of the pancreas by an islet transplant in humans. 
Despite these encouraging results, rejection remains the major 
factor limiting clinical trials of islet transplantation in Type I 
diabetes mellitus.31 .32.3ot-37 The solution to islet rejection cannot be 
provided by an increase in immunosuppressive protocols, since 
islet transplantation does not constitute a life-saving procedure. 
In contrast to other organ transplants such as heart or liver 
allografts, islet administration to Type I diabetic patients should 
be considered as prophylaxis to prevent the development of the 
chronic complications of the disease. Therefore, the risks asso-
ciated with powerful immunosuppressive treatments cannot be 
justified at the present time_ In the absence of any major 
breakthrough in the development of new and more benign 
immunosuppressive agents, it will be necessary to develop 
alternative procedures to prevent islet rejection. 
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Several experimental approaches have been developed to 
reduce the immunogenicity of islet preparations by elimination or 
metabolic inactivation of the donor antigen presenting ceJJs 
(APCs) within the islet grafts. Other approaches to prevent islet 
rejection that are currently under investigation include 
microencapsulationimacroencapsuJation, bioartificial pancreas 
and treatment with antibodies to major histocompatibility com-
plex (MHC) determinants. These approaches are not the subject 
of the present review. Instead this review will address the 
question of the role of APCs in islet rejection and the method to 
develop islet graft .acceptance that could require a participating 
or determining effect of APCs. 
The idea of treating tissues before tranSplantation to reduce 
immunogenicity is not new.38.39 In 1934, Stone suggested a clinical 
benefit of in vitro culture of parathyroid tissue before tranSplan-
tation in patients with hypoparathyroidism. 38 The hypothesis was 
that culture of tissue in the presence of recipient serum could 
result in graft "adaptation" to the new host. Lafferry40 postulated 
that the facilitating effect of organ culture could be explained by 
the destruction or metabolic inactivation of bone marrow-derived 
donor antigen presenting cells (APCs). After two weeks of culture 
in an atmosphere of 95% 0z' Significant prolongation of thyroid 
allograft survival was obtained (> 200 daYS).40·41 Inactivation or 
destruction of the so-called "passenger leukocyres"42.43 became 
the focus of many investigators who significantly contributed to 
developing procedures to prolong survival of endocrine tissues 
44.45 and pancreatic islet ~ grafts. 
Faustman et al50 achieved prolongation of islet allograft 
survival following anti-Ia serum and complement treatment of the 
donor islets prior to transplantation, demonstrating a correlation 
between islet immunogenicity and the presence of Qass II-
positive cells in the transplanted islets. However, it has been 
shown that islet allograft rejection occurs despite Class II identity 
between the donor and the recipient,66 indicating that rejection 
can occur for CJass I disparities alone.67-69 
Steinman and his associates described a specific type of 
interdigitating APC which he called the dendritic cell. He dem-
onstrated that this Qass II+ cell was a potent simulator of immune 
reaction in vitro.'O He prepared a monoclonal antibody (mAb) to 
mouse dendritic cells and demonstrated that treatment with this 
antibody could eliminate these cells in vitro. In collaborative 
studies with Steinman, Faustman et al, demonstrated dendritic 
cells in mouse islets by immunochemical techniques and found 
that these cells could be eliminated by in vitro treatment of the 
islets with the m.o\b and complement. Pretreatment of BlO-BR (H-
Zk) donor mouse islets with the anti-dendritic cell mAb plus 
complement prevented rejection of the treated islets when 
transplanted into MHC-disparate diabetic C;7 BU6J (H-2b) 
recipients.52 These findings indicated that in the mouse the 
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dendritic cell plays a major role in the initiation of rejection of islet 
allografts, since other Ia+ cells which remained in the graft after 
elimination of the dendritic cell did not initiate rejection. 
Subsequent attempts to prevent rejection of rat islet allografts 
using antibodies that were reactive with Ia antigens in these 
species were nor successful. In fact, either treatment of donor 
islets with a single antibody or with a mi'ttUre of anti-Ia antibodies 
and complement did not prevent rejection of rat islet allografts. 
Lacy and his associates demonsu:ued that in the rat, anti-Ia 
antibody and complement treaunent decreased the number and! 
or quality of APCs in the islets but did nor completely eliminate 
them. The inability [0 prevent rejection of rat islet allografts by 
treatment of the donor islets with anti-Ia antibodies was probably 
due to the larger size and more compact arrangement of rat islets 
as compared to mouse islets. thus making it more difficult for the 
antibody and complemem to diffuse into the islets. Ia -;- lymphoid 
cells can be demonstrated in freshly isolated rat islets using 
immunohistocherrucal techniques: however, relatively few Ia+ 
cells can be found after overnight culture. If the cultured islets are 
parrially disrupted by a mechanical me:lns or by a low calcium 
content in the medium. then Ia + cells can be demonstrated in such 
islet preparatiOns. These findings indicated that !a + cells were still 
present in the islets after overnight culture; however. the antibody 
was un:lble to penetrate the tightly compaer islets to reveal their 
presence. The size and compacmess of human islets is similar to 
the rat. and it may be difficult to obtain complete penetration of 
human islets with specific anti-Ia antibodies and complement. 
Thus, the rat model could be of assistance to test approaches that 
may be applicable to human islet transplants.'1 
Evidence is growing that APCs in different tissues are part of 
a bone marrow-derived system connected by movement and 
homingK~ Coupled with this migratory ability is the capacity to 
capture antigens in an immunogenic form in situ. There is 
evidence to suggest that donor APCs from solid organ grafts, Le., 
heart, migrate to splenic and other lymphoid tissues of the host 
and that allograft rejection is in fact initiated at a site distinct from 
the graft itself119 The progenitor for the putative dendritic cell 
lineage has not been isolated. Dendritic cells in spleen and lymph 
originate from a proliferating pool of precursors and undergo 
rapid tumover,"F5 but the site for proliferation (3H-thymidine 
uptake) is not known. A bone marrow precursor exists but 
conditions have not been identified that direct its growth in 
culture.73,7U6.77 
A recent study by Serum et al compared the potency of an 
enriched rat donor-strain dendritic cell population with fractionated 
spleen in relative ability to initiate an immune response in vivo.78 
While 103-104 dendritic cells were capable of stimulating graft 
rejection, or at least a severe immunologic response, 105 spleen 
cells were required to produce a similar effea, indicating that 
dendritic cells are powerful APCs. These flndings extended the in 
vitro evidence that dendritic cells are potent stimulator cells and 
supported the hypothesis that APCs may be one of the most 
important inducers of allograft rejection. 
Increasing interest has been focused on the thymus as a 
unique site for the induction of tolerance to both the endogenous 
(self) and transplantation antigensK~ In radiation bone marrow 
chimeras it is now accepted that bone marrow-derived thymic 
stromal APCs played an essential role in the deletion of potentially 
auto reactive T -lymphocytes during T cell maturation. A renewed 
interest in the thymus as a 'privileged n site for tolerance induction 
has therefore occurred. The induction of systemic donor-specific 
transplantation tolerance for islets but not skin was reported 
when Antilymphocyte Serum (ALS) was administered intraperi-
toneally(IP) and a simultaneous ),!HC-disparate islet allograft was 
placed intrathymically (IT).96 A subsequent donor-specific islet 
graft was accepted at a distant site (renal subcapsular), but third-
parry islet grafts were rejected. Recipients were systematically 
hypore:lctive to donor alloantigens in mixed lymphocyte culrure 
proliferative assays (:'!lR). The thymus was critical for tolerance 
induction since placement of the fIrst graft at the renal subcapsu-
lar CRSe) location did not induce tolerance. One might speculate 
that presence of bone marrow-derived APCs accompanying the 
islet graft could have resulted in the induction of tolerance. This 
is especially imPOrtant since quiescent mature T -cells cannot re-
enter the thymus. while activated T-Iymphocytes can,'" 
Therefore. reJeaion has remained a limitation to survival of 
pancre:ltic islet allografts. The induction of donor-specific trans-
plantation tolerance using bone marrow stem cells to produce 
chimerism. has been suggested as a potential approach to prevent 
rejection of transplanted pancreatic islets. The association between 
bone marrow chime:ism and donor-specific transplantation has 
been recognized for -iO yearsK~· 98-115 The fIrst association be-
tween bone marrow chimeras and tolerance was reported by 
Billingham. Brent and ),ledawar in 1953 when they demonstrated 
the induction of permanent donor-specific transplantation toler-
ance for skin grafts by transplantation of bone marrow cells into 
newborn mouse recipients.98 Subsequendy, numerous methods 
to induce similar tolerance in adult recipients using bone marrow 
transplantation have been reported. 101•1lI Monaco et al demon-
strated prolongation of skin allograft survival in mice treated with 
. ALS followed by a critically timed transfusion of donor bone 
marrow stem cells. lOj.llk Similar tolerance for alloantigens has now 
. been achieved in a number of other species. including the dogllO 
and monkey.llI 
Recently, Ildstad et al developed and characterized a model to 
induce donor-specific transplantation tolerance across a species 
barrier through preparation of fully xenogeneic chimeras (rat -
>mouse).1I6.1I7 Engrafunent of rat bone marrow stem cells in 
mouse recipients was stable, as evidenced by the presence of rat-
derived lymphocytes. myeloid cells, platelets and red blood cells 
up to 12 months after reconstitution with untreated rat bone 
marrow cells. Survival was excellent (>80% at 180 days), and there 
was no evidence of graft-versus-host (GVH) disease. Fully 
xenogeneic chimeras specifically accepted donor-strain rat skin 
grafts but were competent to reject MHC-disparate third party 
mouse and rat skin grafts.lI6.117 We have recently demonstrated 
that long-term acceptance and function of donor-specific pancre-
atic islet xenografts could be achieved in fully xenogeneic 
chimeras without requirement of chronic nonspecific immuno-
suppressive therapy.99.lIXl·Euglycemia resulted within 48 hours 
following the placement of the cellular xenograits under the renal 
capSUle. The pancreatic islet grafts were permanendy accepted 
and remained functional for over eight months following trans-
plantation. 
To determine that the euglycemic stat~ present in the chimeras 
was supported by the islet grafts and not due to rerum of function 
of the native pancreas, we performed seriaI nephrectomies of the 
kidneys bearing the grafts in selected chimeras. Following 
nephrectomy the animals returned to the diabetic state within 24 
hours, further demonstrating that the islet xenografts were 
responsible for maintenance of the euglycemic state. Histologi-
cally, the grafts appeared healthy, and there was evidence for 
insulin positive cells (immunoperoxidase stains). Most impor-
tantly, there was no evidence for chronic rejection. These islets 
were not hand picked and therefore closely approximate the 
cellular grafts currently utilized in human trials. We have recently 
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observed that bone marrow-derived APCs are completely re-
placed in fully xenogeneic chimeras with those of the bone 
marrow donor, suggesting a potential role of donor APCs in the 
tolerance state that is associated with chimerism following bone 
marrow transplantation (manuscript submitted). 
In conclusion, it is apparent that antigen-presenting cells exert 
a central role in islet allograft and xenograft rejection and/or 
tolerance induction" Methods to induce tolerance to islets as well 
as to other organ and tissue grafts using APCs as the target of 
immunoalteration procedures are currently the object of intense 
research. In the past APCs have been the target of procedures to 
eliminate and/or metabolically inactivate these cells to prolong 
islet graft suIVival. Today research evidence supports that APCs 
may play an active role in graft acceptance as well. Further studies 
will unmask the multifaceted role of this critical cellular compo-
nent of tissue and organ grafts. 
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